Adrenal dysfunction in HIV-exposed uninfected infants receiving ritonavir-boosted lopinavir, an HIV protease inhibitor, for the prevention of breastfeeding HIV transmission. An ANRS 12174 substudy.

Michel Polak, Stefan A. Wudy, Nicolas Meda, Michaela F. Hartmann, Chipepo Kankasa, James K Tumwine, Kathleen Laborde, G Justus Hofmeyr, Roselyne Vallo, Nicolas Nagot, Thorkild Tylleskär, Philippe Van de Perre, Stéphane Blanche

Background: We recently demonstrated that both ritonavir-boosted lopinavir (LPV/r) and lamivudine (3TC, a nucleoside analogue) given to breastfed infants can reduce the risk of postnatal HIV transmission (ANRS 12174 trial; Nagot, Lancet 2016). In another setting we previously showed the occurrence of adrenal dysfunction in newborn perinatally exposed to LPV/r leading to acute adrenal insufficiency in premature babies (Simon, JAMA 2011).

Objective and hypotheses: Within the ANRS 12174 trial, the administration, randomly assigned, of LPV/r as a monotherapy prophylaxis up to one year in exposed uninfected infants, as compared to 3TC, offered a unique opportunity to study the potential adrenal impact of LPV/r in infants.

Main results: 96 infants (LPV/r: 49, 3TC: 47) samples were analyzed. A marked increase of dehydroepiandrosterone (DHEA) was observed in LPV/r exposed infants as compared to 3TC (median [IQR]): 3.0 [1.6-4.8] vs 1.4 [0.5-3.5] at W6 and 0.4 [0.0-0.8] vs 0.1 [0.0-0.3] ng/mL at W26 respectively, both p<0.001. In infants with high DHEA level at W6 (>5ng/mL (n=11), other adrenal hormones were also significantly increased as compared with 38 with DHEA < 5 (table).

Conclusion/Interpretation:

- In comparison with lamivudine, LPV/r exposure during the first year of life is associated with a significant, early adrenal dysfunction sustained during exposure.

- This effect may result from the interactions between LPV/r and the immature infant’s adrenal and/or an increased ACTH like effect. Further analyses on samples collected after LPV/r discontinuation will be performed.

- There was no difference in severe adverse events incidence between the two treatment groups in the entire cohort (n=1236), but subtle impact on growth and genital development are actively monitored.